Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details Narrative)

v3.21.1
Stockholders' Equity (Details Narrative) - USD ($)
 12 Months Ended
Dec. 15, 2020
Oct. 06, 2020
Aug. 19, 2020
Jun. 18, 2020
Sep. 30, 2019
Dec. 31, 2020
Jun. 25, 2020
Jun. 24, 2020
Dec. 31, 2019
Preferred stock, shares issued              
Preferred stock, shares outstanding              
Net proceeds from offering           $ 4,625,948      
Common stock, shares authorized           30,000,000 30,000,000 100,000,000 100,000,000
2019 Senior Notes [Member]                  
Debt conversion into shares 247,088                
Restricted Stock Award [Member] | Up-List to the Nasdaq [Member]                  
Number of restricted stock awards vested   214,078              
License Agreement [Member] | Elion Oncology, Inc. [Member]                  
Number of common stock issued during period   825,000              
Price per share   $ 4.00              
Payment for license grant   $ 100,000              
License Agreement [Member] | Aposense, Ltd. [Member]                  
Number of common stock issued during period   625,000              
License Agreement [Member] | Yuhan Corporation [Member]                  
Number of common stock issued during period     250,000     500,000      
Pledge Agreement with PoC [Member]                  
Clinical trial funding commitment         $ 1,800,000        
Reduced clinical trial funding commitment         $ 900,000        
Number of pledged shares forfeited         56,640        
Warrants to purchase common stock, forfeited         56,640        
2018 Private Placement Transactions [Member]                  
Number of common stock issued during period       28,971          
Common Stock [Member] | Anti-Dilution Provision [Member]                  
Number of common stock issued during period   1,156,487       1,156,487      
Public Offering [Member]                  
Number of common stock issued during period   4,800,000              
Price per share   $ 4.00              
Net proceeds from offering   $ 17,100,000              
Public Offering [Member] | License Agreement [Member] | Elion Oncology, Inc. [Member]                  
Number of common stock issued during period   825,000              
Payment for license grant   $ 100,000              
Public Offering [Member] | License Agreement [Member] | Aposense, Ltd. [Member]                  
Number of common stock issued during period   625,000              
Underwritten Public Offering [Member] | DKBK Enterprises, LLC [Member]                  
Debt conversion principal amount and related interest   $ 700,000              
Debt conversion into shares   199,537